Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

PAOLA-1 at 5 years: Maintenance olaparib + bevacizumab support long-term remission in HRD-positive ovarian cancer
22 Apr 2024
bởiNatalia Reoutova
Post hoc analysis of the phase III PAOLA-1/ENGOT-ov25 trial reports respective 5-year progression-free survival (PFS) rates of 72 percent vs 28 percent and 5-year overall survival (OS) rates of 88 percent vs 61 percent for maintenance olaparib plus bevacizumab vs bevacizumab alone in lower-risk homologous recombination deficiency (HRD)–positive patients with newly diagnosed advanced ovarian cancer.


![[Infographic] Hướng dẫn sử dụng thuốc nhỏ mũi đúng cách](https://cdn.mspuat.mims.com/images/articles/huong-dan-su-dung-thuoc-nho-mui-đung-cach-banner-8164974c-c703-48ee-8714-add748406258-square.jpg)





